Personalis (NASDAQ:PSNL) Reaches New 1-Year High - Here's What Happened

Key Points

• Personalis, Inc. shares reached a new 52-week high of $7.98 during trading, closing at $7.78 with a significant trading volume of 164,404 shares.
• Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and an average target price of $7.42, reflecting varied outlooks among brokerages.
• The company reported quarterly earnings of ($0.23) EPS, surpassing estimates, but had revenues of $17.20 million, falling short of the expected $20.12 million.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as $7.98 and last traded at $7.78, with a volume of 164404 shares traded. The stock had previously closed at $7.57.

Analyst Ratings Changes

Several brokerages recently commented on PSNL. Wall Street Zen upgraded shares of Personalis from a "sell" rating to a "hold" rating in a report on Saturday, September 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Personalis in a research report on Saturday, September 27th. HC Wainwright reaffirmed a "buy" rating and set a $8.50 price target on shares of Personalis in a research report on Monday, September 8th. Finally, BTIG Research set a $6.00 price target on shares of Personalis in a research report on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Personalis has a consensus rating of "Moderate Buy" and an average target price of $7.42.

Personalis Price Performance

The firm has a market capitalization of $707.67 million, a P/E ratio of -6.23 and a beta of 1.83. The business's 50-day moving average is $5.46 and its 200 day moving average is $5.16.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $20.12 million. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Personalis

A number of large investors have recently bought and sold shares of the company. ARK Investment Management LLC grew its stake in Personalis by 6.1% during the first quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company's stock worth $25,231,000 after buying an additional 412,762 shares in the last quarter. AIGH Capital Management LLC raised its holdings in Personalis by 4.5% in the 1st quarter. AIGH Capital Management LLC now owns 3,968,948 shares of the company's stock valued at $13,931,000 after buying an additional 169,884 shares during the last quarter. Aberdeen Group plc raised its holdings in Personalis by 3.2% in the 2nd quarter. Aberdeen Group plc now owns 1,759,497 shares of the company's stock valued at $11,542,000 after buying an additional 54,713 shares during the last quarter. Blue Water Life Science Advisors LP raised its holdings in Personalis by 42.6% in the 2nd quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company's stock valued at $10,997,000 after buying an additional 500,900 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Personalis by 165.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company's stock valued at $8,960,000 after buying an additional 851,422 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.